Cargando…

Why some people tolerate the second dose of a vaccine but not the first dose

Detalles Bibliográficos
Autores principales:	Yu, Yihua Bruce, Briggs, Katharine T., Taraban, Marc B.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American College of Allergy, Asthma & Immunology. Published by Elsevier Inc. 2022
Materias:	Correspondence
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8963752/ https://www.ncbi.nlm.nih.gov/pubmed/35365254 http://dx.doi.org/10.1016/j.anai.2022.01.033

Ejemplares similares

Preventive Pharmacovigilance: timely and precise prevention of adverse events through person-level patient screening and dose-level product surveillance
por: Yu, Yihua Bruce, et al.
Publicado: (2023)

Correction: Preventive Pharmacovigilance: timely and precise prevention of adverse events through person-level patient screening and dose-level product surveillance
por: Yu, Yihua Bruce, et al.
Publicado: (2023)

All vials are not the same: Potential role of vaccine quality in vaccine adverse reactions
por: Bruce Yu, Yihua, et al.
Publicado: (2021)

Sedimentation behavior of quality and freeze-damaged aluminum-adjuvanted vaccines by wNMR
por: Briggs, Katharine T., et al.
Publicado: (2023)

VITT and Second Doses of Covid-19 Vaccine
por: Lacy, Joanne, et al.
Publicado: (2021)

Grand Challenges in Pharmaceutical Research Series: Ridding the Cold Chain for Biologics
por: Yu, Yihua Bruce, et al.
Publicado: (2021)

Excipient Innovation Through Precompetitive Research
por: Yu, Yihua Bruce, et al.
Publicado: (2021)

COVID-19 vaccine efficacy data: solid enough to delay second dose?
por: Robertson, John F R, et al.
Publicado: (2021)

Delayed second dose of the BNT162b2 vaccine: innovation or misguided conjecture?
por: Robertson, John F R, et al.
Publicado: (2021)

Antibody Persistence through 6 Months after the Second Dose of mRNA-1273 Vaccine for Covid-19
por: Doria-Rose, Nicole, et al.
Publicado: (2021)

COVID-19 vaccine efficacy data: solid enough to delay second dose? – Authors' reply
por: Amit, Sharon, et al.
Publicado: (2021)

Venous sinus thrombosis after the second dose of SARS-CoV-2 vaccine administration
por: Mungmunpuntipantip, Rujittika, et al.
Publicado: (2022)

How important is the second dose of the COVID-19 mRNA vaccine?
por: Liu, Anne Y.
Publicado: (2021)

Accessing first doses of mpox vaccine made available in Victoria, Australia
por: Chow, Eric P.F., et al.
Publicado: (2023)

Reply to “How important is the second dose of the COVID-19 mRNA vaccine?”
por: Shaker, Marcus S., et al.
Publicado: (2021)

Aphasia seven days after second dose of an mRNA-based SARS-CoV-2 vaccine
por: Finsterer, Josef, et al.
Publicado: (2021)

Response to additional COVID-19 vaccine doses in people who are immunocompromised: a rapid review
por: Parker, Edward P K, et al.
Publicado: (2022)

Second-dose COVID-19 vaccines are well tolerated in patients with allergic reactions to the first dose – a single center experience
por: Puxkandl, Viktoria, et al.
Publicado: (2022)

Antibody response to coronavirus disease 2019 vaccines after allergic reaction to first dose: Correspondence
por: Mungmunpuntipantip, Rujittika, et al.
Publicado: (2022)

Reply to the letter “Venous sinus thrombosis after the second dose of SARS-CoV-2 vaccine administration” by Mungmunpuntipantip and Wiwanitkit
por: Finsterer, Josef
Publicado: (2022)

High Uptake of Three COVID-19 Vaccine Doses Among Liver Transplant Recipients
por: Schell, Trevor L., et al.
Publicado: (2023)

Cohort experience of second messenger RNA vaccine dose tolerance after an initial-dose reaction
por: Eastman, Jacqueline, et al.
Publicado: (2022)

Collective and individual rationality dilemma and the failure of anti-Covid-19 policies: Why some people don't wear masks?
por: Nejad, Farhad Nosrati, et al.
Publicado: (2022)

Split-dosing of coronavirus disease 2019 vaccines
por: Mungmunpuntipantip, Rujittika, et al.
Publicado: (2022)

Psoriatic arthritis flare-up after a second dose of BNT162b2 COVID-19 mRNA vaccine
por: Watabe, Daisuke, et al.
Publicado: (2022)

Full-dose NSAIDs at the first sign of respiratory infection?
por: Donzelli, Alberto
Publicado: (2022)

Impaired response to first SARS‐CoV‐2 dose vaccination in myeloproliferative neoplasm patients receiving ruxolitinib
por: Guglielmelli, Paola, et al.
Publicado: (2021)

Serological responses to the first four doses of SARS-CoV-2 vaccine in patients with inflammatory bowel disease
por: Quan, Joshua, et al.
Publicado: (2022)

Uptake of third doses of SARS-CoV-2 vaccines among people with inflammatory bowel disease in Ontario, Canada
por: Kuenzig, M Ellen, et al.
Publicado: (2022)

Antibody response after second BNT162b2 dose in allogeneic HSCT recipients
por: Redjoul, Rabah, et al.
Publicado: (2021)

A three-dose inactivated SARS-CoV-2 vaccine is sufficient to elicit humoral immune responses in people living with HIV-1
por: Yu, Haisheng, et al.
Publicado: (2023)

Antibody persistence 100 days following the second dose of BNT162b mRNA Covid19 vaccine in patients with chronic lymphocytic leukemia
por: Tadmor, Tamar, et al.
Publicado: (2021)

Three-dose vaccination elicits neutralising antibodies against omicron
por: Wu, Mary, et al.
Publicado: (2022)

COVID-19 booster doses in pregnancy and global vaccine equity
por: Kalafat, Erkan, et al.
Publicado: (2022)

Conformational transition of a non-associative fluorinated amphiphile in aqueous solution. II. Conformational transition vs. supramolecular assembly
por: Taraban, Marc B., et al.
Publicado: (2019)

Full-dose NSAIDs at the first sign of respiratory infection? – Authors’ reply
por: Ruggenenti, Piero, et al.
Publicado: (2022)

Safety and tolerability of mRNA COVID-19 vaccines in people with antiphospholipid antibodies
por: Sciascia, Savino, et al.
Publicado: (2021)

Matching target dose to target organ
por: Bannon, Desmond I., et al.
Publicado: (2017)

A Randomized Clinical Trial Using CoronaVac or BNT162b2 Vaccine as a Third Dose in Adults Vaccinated with Two Doses of CoronaVac
por: Mok, Chris Ka Pun, et al.
Publicado: (2022)

The second dose of the BNT162b2 mRNA vaccine does not boost SARS-CoV-2 neutralizing antibody response in previously infected subjects
por: Vicenti, Ilaria, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_hqkuo97h71e8r106cfa9gclajf